Pancreatic cancer genes
AssigneeChiron Corporation
InventorGiulia C. Kennedy
Life of this patent
Estimating the term…
Abstract
The present invention provides the art with the DNA coding sequences of polynucleotides that are up- or down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.
Claims21
An isolated subgenomic polynucleotide comprising at least twelve contiguous nucleotides selected from the group consisting of the polynucleotide sequences as shown in SEQ ID NOS:1-15.
An isolated subgenomic polynucleotide comprising at least twelve contiguous nucleotides selected from the group consisting of the polynucleotide sequences of SEQ ID NOS:2, 5 and 15.
An isolated polypeptide, wherein said polypeptide comprises at least 6 contiguous amino acids encoded by a polynucleotide selected from the group consisting of the polynucleotide sequences shown in SEQ ID NOS:1-15.
An isolated polypeptide, wherein said polypeptide comprises at least 6 contiguous amino acids encoded by a polynucleotide selected from the group consisting of the polynucleotide sequences shown in SEQ ID NOS:2, 5 and 15.
An isolated nucleotide probe consisting of a sequence selected from the group consisting of the polynucleotide sequences shown in SEQ ID NOS:1-15.
A method of diagnosing dysplasia comprising the steps of.
- determining the amount of a polypeptide expressed from a polynucleotide having a sequence selected from the group consisting of the polynucleotide sequences shown in SEQ ID NOS:1, 3-4, 6-11, and 13-14 in a sample human tissue suspected of being dysplastic and in a human tissue which is normal, and
- comparing the determined amounts, wherein a sample human tissue which contains more of the polypeptide than the normal tissue is identified as being dysplastic.
A method of diagnosing dysplasia comprising the steps of:
- determining the amount of mRNA molecules in a sample human tissue suspected of being dysplastic and in a human tissue which is normal, wherein said mRNA molecules are complementary to the minus strand of a double-stranded sequence, wherein said double-stranded polynucleotide sequence is selected from the group of polynucleotides as shown in SEQ ID NOS:1, 3-4, 6-11, and 13-14, and
- comparing the determined amounts of mRNA molecules;
- wherein a sample human tissue which contains more of the mRNA molecules than the normal tissue is identified as being dysplastic.
A method of diagnosing cancer comprising the steps of
- determining the amount of a first set of mRNA molecules in a sample human tissue suspected of being cancerous and in a human tissue which is normal, wherein said mRNA molecules are complementary to the minus strand of a double-stranded polynucleotide sequence, wherein said double-stranded polynucleotide sequence is selected from the group of polynucleotides as shown in SEQ ID NOS:1, 3-4, 6-11, and 13-14;
- and
- determining the amount of a second set of mRNA molecules in a sample human tissue suspected of being cancerous and in a human tissue which is normal, wherein said mRNA molecules are complementary to the minus strand of a double-stranded sequence, wherein said double-stranded polynucleotide sequence is selected from the group of polynucleotides as shown in SEQ ID NOS:2, 5, and 15, and
- comparing the determined amounts;
- wherein a proband human tissue which contains more of the second set of mRNA molecules than the normal tissue, and which contains substantially same amount of the first set of mRNA molecules, as compared to the normal tissue, is identified as cancerous.
Dependencies are inferred from the claim text.